Chinese Nucleic Acid Drug Developers Dominate October VC/PE Funding

 
• By Dexter Jie Yan

Sirius Therapeutics’ $60m series B signified venture capital firms’ reviving interest in Chinese developers of nucleic acid drugs. Meanwhile, Angitia Biopharmaceuticals’ $46m series B extension round underscored investors’ attention to the musculoskeletal diseases area.

FUNDING word written on wood block
Venture capital, private equity investors showed renewed interest in October in nucleic acid modalities. • Source: Shutterstock

More from China

More from Focus On Asia